• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Producer positions PPA for regulatory approval

May 1, 2003
Jennifer Fiala

Pensacola, Fla.- PRN Pharmacal is urging the Food and Drug Administration (FDA) to fully approve phenylpropanolamine (PPA) as a new animal drug and pledges $2 million to study it for exclusive label rights - a move that's caught the attention of at least one manufacturing competitor.

Pensacola, Fla.- PRN Pharmacal is urging the Food and Drug Administration (FDA) to fully approve phenylpropanolamine (PPA) as a new animal drug and pledges $2 million to study it for exclusive label rights - a move that's caught the attention of at least one manufacturing competitor.

Pensacola, Fla.-based PRN is one of three pharmaceutical companies marketingPPA products to treat urinary incontinent dogs. In January 2001, FDA officialspulled the drug from the market after a study linked its presence in dietarysupplements and nasal decongestants to hemorrhage stroke cases in women.Consequently, veterinarians lost their off-label PPA sources.

But it wasn't long before PRN and at least two other manufacturers, Europe-basedVétoquinol and Veterinary Products Laboratories (VPL) out of Phoenix,Ariz., resumed PPA production. As PRN received regulatory discretion withthe FDA's Center for Drug Evaluation and Regulation (CDER) to manufacturethe PPA drug Proin, so did Vétoquinol and VPL, which market Propalinand Cystolamine, respectively.

PRN representatives suggest widespread need for PPA in the companionanimal market, citing urinary incontinence in nearly 20 percent of all spayedfemale dogs.

"We knew when PPA was removed from over-the-counter human productsthat this would put many dogs at risk," says Gary Cushing, PRN vicepresident of sales. "Many pet owners will only put up with so muchdribbling. So PRN made the decision to finance the testing that would berequired to keep Proin PPA available for veterinary use."

Facing the competition

Of course, the companies each have their own marketing literature. WhilePRN officials maintain the company is "by far the market leader"in PPA sales with Proin effective in more than 94 percent of dogs tested,Vétoquinol representatives challenge the competitor's claims. Bothprivate companies won't publicize actual sales data, but Vétoquinolspokesman Rich Shavelson says his company has long-remained the world'sPPA production leader with its most recent addition of U.S. and Canadianveterinary markets.

"We're by far the largest marketer worldwide," he says. "Itis registered in every country in the world and presently under regulatorydiscretion for the U.S. We definitely think we've got a good product.

"Our mission is to educate the client. We have better selling aidsand educational materials than our competitors."

VPL representatives did not return phone calls seeking comment.

Advertisement

Race to label?

PRN spokesman Matt DeWeese admits the regulatory process likely willtake several years before Proin is fully approved for veterinary use, butinsists "the company will get a label on it."

In the meantime, Shavelson says he's not too concerned.

"We were going to try and get it approved, but when we found out(PRN) was doing it, we figured 'what's the point?'" he says. "Urinaryincontinence in dogs is huge; it's like a mini heartworm market. It'll takeyears before the FDA makes any decisions on this." n

PPA FOR SALE

n No less than three pharmaceutical companies manufacture phenylpropanolamine,commonly known as PPA, in the United States as a treatment for urinary incontinencein dogs. For years, the drug was prescribed off-label by veterinarians beforethe Food and Drug Administration (FDA) removed it from the human drug marketin 2001. Since then, federal drug regulators have temporarily reprievedPPA for veterinary use only. The following is currently available:

Proin, manufactured by PRN Pharmacal, Pensacola, Fla. The drug comesavailable in 75-milligram, 50-milligram and 25-milligram liver-flavoredchewable tablets and 25-milligram drops. Package sizing ranges from 60-countto 180-count bottles.

Cystolamine, manufactured by Veterinary Products Laboratories, Phoenix.The drug comes in 75-milligram capsules packaged in 60-count and 500-countbottles.

Propalin, manufactured by European company Vétoquinol. The drugcomes 60-count bottles of 25-milligram chewable tablets as well as 30-milliliterto 100-milliliter syrup vials.


Advertisement

Latest News

Communicating the importance of genetic screening

Purina announces its 2023 Pet Care Innovation Prize winners

AmeriVet Veterinary Partners deemed a 2022 Business of the Year

This week on dvm360.com: The Vet Blast Podcast kicks off National Pet Dental Health Month

View More Latest News
Advertisement